A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most important tool to control pain in rheumatic diseases; however, their application is limited by the risk of serious complications in the cardiovascular system and gastrointestinal tract (GIT). The advent of a Russian new drug that is a naprox...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/472 |
| _version_ | 1797876830245486592 |
|---|---|
| author | Andrei Evgenyevich Karateev L I Alekseeva S G Anikin |
| author_facet | Andrei Evgenyevich Karateev L I Alekseeva S G Anikin |
| author_sort | Andrei Evgenyevich Karateev |
| collection | DOAJ |
| description | Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most important tool to control pain in rheumatic diseases; however, their application is limited by the risk of serious complications in the cardiovascular system and gastrointestinal tract (GIT). The advent of a Russian new drug that is a naproxen and esomeprazole combination (Vimovo™) extends the possibilities of NSAIDS use. This review considers the benefits of both NEC components. The former is naproxen, a traditional NSAIDS that is in common use as an effective analgesic worldwide. Its chief merit is the least cardiovascular risk among all NSAIDs (aside from aspirin). Esomeprazole is a representative of the group of proton pump inhibitors, a potent antisecretory drug that has passed major tests as an agent for the prevention of NSAID-related GIT complications. This drug combination allows patient incompliance to gastroprotective therapy to be eliminated. Large-scale clinical trials have confirmed a considerable reduction in the frequency of GIT complications with NSAIDS use as compared to the standard enteric-coated naproxen, including in patients receiving low-dose aspirin. Comparison of NEC with celecoxib has indicated that the new medication is as effective as a selective COX-2 inhibitor in both efficacy and GIT safety. |
| first_indexed | 2024-04-10T02:07:28Z |
| format | Article |
| id | doaj.art-5dfc4c704a274f85b8bc7fed08caa397 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:07:28Z |
| publishDate | 2013-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-5dfc4c704a274f85b8bc7fed08caa3972023-03-13T08:39:23ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2013-03-0171829310.14412/1996-7012-2013-23741777A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risksAndrei Evgenyevich KarateevL I AlekseevaS G AnikinNonsteroidal anti-inflammatory drugs (NSAIDs) are the most important tool to control pain in rheumatic diseases; however, their application is limited by the risk of serious complications in the cardiovascular system and gastrointestinal tract (GIT). The advent of a Russian new drug that is a naproxen and esomeprazole combination (Vimovo™) extends the possibilities of NSAIDS use. This review considers the benefits of both NEC components. The former is naproxen, a traditional NSAIDS that is in common use as an effective analgesic worldwide. Its chief merit is the least cardiovascular risk among all NSAIDs (aside from aspirin). Esomeprazole is a representative of the group of proton pump inhibitors, a potent antisecretory drug that has passed major tests as an agent for the prevention of NSAID-related GIT complications. This drug combination allows patient incompliance to gastroprotective therapy to be eliminated. Large-scale clinical trials have confirmed a considerable reduction in the frequency of GIT complications with NSAIDS use as compared to the standard enteric-coated naproxen, including in patients receiving low-dose aspirin. Comparison of NEC with celecoxib has indicated that the new medication is as effective as a selective COX-2 inhibitor in both efficacy and GIT safety.https://mrj.ima-press.net/mrj/article/view/472ревматические заболеваниянестероидные противовоспалительные препаратыгастропротективная терапияфиксированная комбинация напроксена и эзомепразола |
| spellingShingle | Andrei Evgenyevich Karateev L I Alekseeva S G Anikin A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks Современная ревматология ревматические заболевания нестероидные противовоспалительные препараты гастропротективная терапия фиксированная комбинация напроксена и эзомепразола |
| title | A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| title_full | A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| title_fullStr | A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| title_full_unstemmed | A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| title_short | A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| title_sort | combination of naproxen and esomeprazole analgesic therapy on balancing cardiovascular and gastrointestinal risks |
| topic | ревматические заболевания нестероидные противовоспалительные препараты гастропротективная терапия фиксированная комбинация напроксена и эзомепразола |
| url | https://mrj.ima-press.net/mrj/article/view/472 |
| work_keys_str_mv | AT andreievgenyevichkarateev acombinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks AT lialekseeva acombinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks AT sganikin acombinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks AT andreievgenyevichkarateev combinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks AT lialekseeva combinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks AT sganikin combinationofnaproxenandesomeprazoleanalgesictherapyonbalancingcardiovascularandgastrointestinalrisks |